Premium
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols
Author(s) -
Sobas Marta,
RodriguezVeiga Rebeca,
Vellenga Edo,
Paluszewska Monika,
De la Serna Javier,
GarcíaÁlvarez Flor,
Gil Cristina,
Brunet Salut,
Bergua Juan,
GonzálezCampos Jose,
Ribera José María,
Tormo Mar,
González Marcos,
Fernández Isolda,
Benavente Celina,
GonzálezSanmiguel Jose D.,
Esteve Jordi,
PérezEncinas Manuel,
Salamero Olga,
Manso Felix,
Lowenberg Bob,
Sanz Miguel A.,
Montesinos Pau
Publication year - 2020
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13346
Subject(s) - overweight , medicine , body mass index , underweight , obesity , acute promyelocytic leukemia , multivariate analysis , incidence (geometry) , risk factor , pediatrics , biochemistry , retinoic acid , chemistry , physics , optics , gene
Objective The obesity/overweight may have an influence on APL outcomes. Methods This is the biggest multicentre analysis on 1320 APL patients treated with AIDA‐induction and risk‐adapted consolidation between 1996 and 2012. Patients body mass index (BMI) was classified as underweight (<18.5 kg/m 2 ), normal (18.5‐25 kg/m 2 ), overweight (25‐29.9 kg/m 2 ), and obese (≥30 kg/m 2 ) according to the World Health Organization (WHO) criteria. Results and conclusions Relationship between male gender, older age, and other known laboratory abnormalities in overweight/obese patients was significant. The induction mortality rate was significantly higher in APL with BMI ≥25 vs BMI <25 (10% vs 6%; P = .04). APL patients with BMI ≥25 had a trend to lower OS (74% vs 80%; P = .06). However, in the multivariate analysis, BMI did not retain the independent predictive value ( P = .46). There was no higher incidence of differentiation syndrome with BMI ≥25, but there was a trend in obese. There was no difference in relapse rate according to the BMI. In summary, overweight/obesity does not represent an independent risk factor for APL outcomes. The influence of obesity in APL patients treated with chemotherapy‐free regimens remains to be established.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom